A single-center, open-label, phase i study of single-agent GMX1777 administered as a 24-hour infusion every 3 weeks to patients with refractory solid tumors or lymphomas

Trial Profile

A single-center, open-label, phase i study of single-agent GMX1777 administered as a 24-hour infusion every 3 weeks to patients with refractory solid tumors or lymphomas

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2013

At a glance

  • Drugs Teglarinad chloride (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Sep 2010 Status changed from active, no longer recruiting to withdrawn prior to recruitment, according to ClinicalTrials.gov.
    • 13 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 25 Oct 2008 Results presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, according to a Gemin X media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top